9 results about "Premature ageing" patented technology

WATER-SOLUBLE EXTRACT FROM A PLANT OF THE PRUNUS SPECIES TO PREVENT THE DELETE EFFECTS OF THE EXPOSOME. The present invention relates to the use of a flower extract from a plant of the Rosaceae family and the Prunus genus, or a composition thereof, to protect the skin from the deleterious effects of the exposome, including disruption of the barrier function, neurogenic inflammation, irritation, and oxidative stress. The invention is thus intended to prevent the clinical signs of premature aging, including the appearance of hyperpigmentation spots responsible for loss of skin tone uniformity and skin hyperreactivity.

The application discloses application of cell endogenous metabolites in preparation of medicines for treating and / or preventing aging. The cell endogenous metabolites are any one or combination of phosphocreatine, hypotaurine and / or phosphoethanolamine. The application finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively restore cell growth, reduce cell SA-beta-Gal staining intensity, improve cell mitochondrial function and increase ATP yield, restore cell mitochondrial membrane potential, alleviate damage caused by cell oxidative stress and premature aging, and also prolong the life of nematodes and restore exercise capacity in the middle of aging. Meanwhile, the three metabolites have a synergistic effect, and by adjusting the matching concentration of the three metabolites, the same cell protection effect can be achieved by mixed administration. Since the endogenous metabolites are accurate, efficient and safe, the three cell endogenous metabolites provided by the application can be used for preparing anti-aging medicines.

This invention provides a method, system, and storage medium for assessing the vascular physiological age of hypertensive patients, belonging to the field of intelligent medical technology. The method includes: acquiring assessment data to characterize the vascular state of hypertensive patients, and constructing a sequence of vascular feature parameters based on the assessment data; inputting the vascular feature parameter sequence into a pre-trained vascular physiological age prediction model to perform feature learning processing, and outputting vascular physiological age parameters; inputting the vascular physiological age parameters into a time-series analysis model to perform trend analysis processing, generating longitudinal aging feature parameters; judging the degree of premature aging of blood vessels based on the longitudinal aging feature parameters, and outputting the vascular physiological age assessment result of the hypertensive patient. This invention achieves reliable processing of the vascular physiological age and stable assessment of the degree of premature aging for individual hypertensive patients.

The present invention relates to a method for identifying the aging degree of a subject or a tissue or organ thereof, and for evaluating the effect of anti-aging interventions. Specifically, provided is a method for identifying the aging degree of a subject or a cell, tissue or organ thereof, or for evaluating the biological age of the subject or diagnosing premature aging disorders, which method predicts the aging status of a tissue or organ of a subject on the basis of the levels of DNA methylation, gene transcripts, proteins or metabolites. The present invention further relates to the use of metformin in the preparation of a drug for treating, preventing or delaying aging-related diseases or conditions in primates, preferably humans.

The invention discloses a premature ovarian failure rat animal model building method based on enterovirus group transplantation, and particularly relates to the technical field of animal model building. According to the invention, the enterovirus group of a premature ovarian failure patient is subjected to in-vitro extraction and purification, and then is transplanted into a female rat, so that a new experimental model is provided for researching the interaction between the enterovirus group and the premature ovarian failure; meanwhile, a new way is opened up for further revealing the research on the complex relation between intestinal microorganisms and female reproductive health. In addition, the model is expected to provide an experimental basis for developing a novel treatment strategy for premature ovarian failure. The method aims to deeply explore the relationship between the enterovirus / bacteriophage group and female reproductive system diseases, especially premature ovarian failure.

The application discloses a Caenorhabditis elegans disease model and a construction method and application thereof, and particularly relates to a Caenorhabditis elegans disease model for neurodegenerative diseases, which comprises Caenorhabditis elegans, wherein a fragment of NOTCH2NLC GGC is overexpressed in the Caenorhabditis elegans, the sequence of the fragment is shown as SEQ ID NO. 1, and the neurodegenerative diseases include NIID. The application overcomes the difficulty of cloning GGC repeat sequences, successfully overexpresses 100 GGC repeat sequences of a human NOTCH2NLC gene in Caenorhabditis elegans, and shows similar behavior disorders and premature aging symptoms to human NIID diseases. The model is a good animal model for studying the pathogenic mechanism of GGC repeat sequences of the NOTCH2NLC gene and drug screening.

The application discloses a polypeptide UPCP and application thereof in preparation of anti-aging products. The polypeptide UPCP provided by the application has an amino acid sequence of sequence 4 in the sequence list. The polypeptide is applied in preparation of products with any one of the following functions: 1) treating children's premature aging; 2) delaying physiological aging of mammals or cells thereof; 3) improving premature aging of mammals; the improvement of premature aging of mammals is embodied in delaying premature aging of mammals; 4) improving body weight of premature aging animals; the improvement of body weight of premature aging animals is embodied in increasing body weight of premature aging animals; 5) relieving motor dysfunction of premature aging animals; 6) prolonging survival period of premature aging animals, etc. The application develops a specific peptide (UPCP) which can inhibit HGPS cell aging, improve aging characteristics of HGPS premature aging mice and prolong survival period, and provides a new strategy for treatment of HGPS.

The diagnostic procedure for premature aging of a grape-based alcoholic beverage susceptible to premature aging involves taking a sample of the alcoholic beverage, which is divided into three parts. The first part is subjected to chemical analysis to determine the concentration of a predetermined characteristic marker correlated with premature aging. The second part is subjected to analysis to determine a value for at least one antioxidant concentration. The third part is subjected to accelerated aging corresponding to natural aging for a duration Δt, then to chemical analysis to determine a value for the predetermined characteristic marker correlated with premature aging. A parameter representative of premature aging is then determined from these values. (See Figure 1 for abbreviations.)